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In accordance with World Health Organization guide-
lines, the Dutch Ministry of Health, Welfare and Sports
designed a national plan to minimize effects of pandemic
influenza. Within the scope of the Dutch pandemic pre-
paredness plan, we were asked to estimate the magnitude
of the problem in terms of the number of hospitalizations
and deaths during an influenza pandemic. Using scenario
analysis, we also examined the potential effects of inter-
vention options. We describe and compare the scenarios
developed to understand the potential impact of a pandem-
ic (i.e., illness, hospitalizations, deaths), various interven-
tions, and critical model parameters. Scenario analysis is a
helpful tool for making policy decisions about the design
and planning of outbreak control management on a nation-
al, regional, or local level. 
I
n 1997, avian influenzavirus was shown to infect
humans directly when an influenza virus A/H5N1 infect-
ed 18 people in Hong Kong; of those, six died (1,2). After
this event, experts predicted that another influenza pan-
demic is highly likely, if not inevitable (3,4). The impact of
a pandemic depends on factors such as the virulence of the
pandemic virus and the availability of a vaccine. Because
development is time-consuming, the vaccine would likely
not be available in the early stages of a pandemic, and a
major vaccine shortage would be expected (5). An influen-
za virus pandemic would likely cause substantial social
disruption because of high rates of illness, sick leave, hos-
pitalization, and death.  Therefore, pandemic planning is
essential to minimize influenza-related illness, death, and
social disruption (5,6). 
In accordance with World Health Organization guide-
lines, the Dutch Ministry of Health, Welfare and Sports
developed a national plan to minimize or avert effects of
pandemic influenza. Within the scope of the Dutch pan-
demic preparedness plan, we were asked to estimate the
magnitude of the problem in terms of the expected number
of hospitalizations and deaths during an influenza pandem-
ic. We also estimated the potential effects of intervention
options, including the use of the relatively new antiviral
drugs, neuraminidase inhibitors (7,8).
One published study (9) has estimated the economic
effects of an influenza pandemic. Meltzer et al. examined
the possible effects of influenza vaccine-based interven-
tions in terms of outpatient visits, hospitalizations, deaths,
and related costs during a pandemic in the United States.
More recently, different strategies for the control of inter-
pandemic influenza for the elderly population in three
European countries (England and Wales, France, and
Germany) have been evaluated (10). Our objective was to
examine the potential impact of pandemic influenza in the
Netherlands and to analyze the effects of several (other
than influenza vaccine–based) possible interventions in
terms of hospitalizations and deaths. 
Methods
Predicting when the next influenza pandemic will occur
and how it will evolve is impossible, and the same is true
for forecasting the number of persons who will become ill,
be hospitalized, or die. Because of the many uncertainties,
we performed a scenario analysis (11) that included con-
sulting of experts and modeling. At a meeting of experts
held to discuss an influenza pandemic in the Netherlands,
specialists on influenza (virology, epidemiology, and sur-
veillance) and on controlling epidemics and disasters gave
their opinions about the formulated intervention scenarios,
the assumptions made, and the value of critical parameters
(12). Amodel was used to estimate the number of hospital-
izations and deaths in the Netherlands for different scenar-
ios.  We also compared the number of expected hospital-
izations and deaths for each of the different intervention
scenarios to the number expected for the nonintervention
scenario. 
Scenarios
Various scenarios are possible, depending on whether
influenza vaccine, pneumococcal vaccine, or antiviral
drugs are available (among other factors). In all scenarios,
we assumed a gross attack rate of 30%; we also assumed
age-specific attack, hospitalization, and death rates and
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Bilthoven, the Netherlands healthcare utilization (e.g., antibiotic drug prescription) as
in a regular epidemic. Table 1 shows the base-case
assumptions in the various scenarios. Following are
descriptions of the scenarios considered relevant and suffi-
ciently realistic by the specialists who participated in the
meeting of experts.
Nonintervention Scenario
The nonintervention scenario is a “worst case” situation
in which no intervention is possible. The scenario includes
a pandemic influenza for which no vaccine is available and
only regular care and regularly prescribed antibiotic drugs
are provided. In the base case, we assume a gross attack
rate of 30%; an age-specific attack; and hospitalization,
death rates, and healthcare utilization as in a regular epi-
demic.
Influenza Vaccination Scenario 
In this scenario, when an influenza vaccine becomes
available, two possible strategies are considered: 1) vacci-
nation of risk groups including persons >65 years of age (n
= 2.78×106) and healthcare workers (n = 0.80×106) and 2)
vaccination of the total population (n = 15.6×106). In the
base case, influenza vaccination is assumed to be 56%
effective in preventing hospitalizations and deaths in per-
sons >65 years of age (15), and 80% effective in those <64
years of age (Table 1) (13,14).
Pneumococcal Vaccination Scenario 
In the absence of a vaccine available at the beginning of
a pandemic, the Dutch Health Council recommends pro-
viding influenza risk groups (including those >65 years of
age; n = 2.78×106) with pneumococcal vaccination (18),
which is a 23-valent vaccine assumed to prevent invasive
infections caused by Streptococcus pneumoniae, one of the
possible complications of influenza. For the base case, we
assumed that 50% of hospitalizations and deaths from
influenza-related pneumonia are caused by invasive pneu-
mococcal infection and that pneumococcal vaccination
prevents 80% of invasive infections caused by vaccine
serotypes (Table 1) (16,17). In the Netherlands, 80% of
serotypes involved in invasive pneumococcal infections
are covered by the 23-valent vaccine, which results in a
vaccine effectiveness of 64% against invasive pneumococ-
cal infections.
Therapeutic Use of Neuraminidase 
Inhibitors Scenario 
This scenario includes the use of neuraminidase
inhibitors. When taken within 48 hours after onset of
symptoms and continued for 5 days, neuraminidase
inhibitors (zanamivir and oseltamivir) (19) reduce the
duration and seriousness of influenza by 1 to 2 days for
adults (20–24), children (22,25,26), and persons at high
risk (22,27–29). However, the effectiveness of neu-
raminidase inhibitors for preventing hospitalizations and
deaths (our outcome parameters) is unknown. Therefore,
we assumed that 25% to 75% of the hospitalizations and
deaths attributed to influenza would be avoided by thera-
peutic use of neuraminidase inhibitors (12) in this scenario
(each person with an influenzalike illness begins the med-
ication within 48 hours after the first symptoms). An
advantage of therapeutic use of neuraminidase inhibitors is
that antibodies are formed (26) because infection is not
prevented; thus protection against an infection resulting
from the same virus is built up, as in an untreated infection. 
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Table 1. Assumptions made for influenza pandemic scenario analysis, the Netherlands 
Scenario  Assumptions in base case  Assumptions in sensitivity analysis 
No intervention   Gross attack rate of 30%; age-specific attack, 
hospitalization, and death rates as in regular 
epidemic; and healthcare utilization as in regular 
epidemic. 
Gross attack rate of 10% and 50%; age-specific 
attack rates (see Table 4); and complication rates 
for a) persons <64 y of age x 2 and b) persons at 
low risk equal to persons at high risk.  
Influenza vaccination of 
risk groups (including persons >65 y 
of age) and healthcare workers 
 
Gross attack rate of 30%; age-specific attack, 
hospitalization, and death rates as in regular 
epidemic; and vaccine efficacy 80% (<64 y of 
age) (13,14) and 56% (>65 y) (15) to prevent 
hospitalizations and deaths 
 
Gross attack rate of 10% and 50%; age-specific 
attack rates (see Table 4); complication rates for a) 
age group <64 y times 2 and b) persons at low risk 
equal to persons at high risk; influenza vaccine 
efficacy a) 80% for all ages and b) 40% for age 
group <64
a and 30% for age group >65
b. 
Pneumococcal vaccination of 
influenza of risk groups (including 
persons aged >65 y)  
Gross attack rate of 30%; age-specific attack, 
hospitalization, and death rates as in regular 
epidemic; 50% pneumococcal-related 
hospitalizations; and vaccine efficacy 64% against 
invasive infections (16,17). 
Gross attack rate of 10% and 50%; age-specific 
attack rates (see Table 4); complication rates for a) 
persons <64 y of age x 2 and b) persons at low risk 
equal to persons at high risk; 25% and 75% 
pneumococcal-related hospitalizations; and vaccine 
efficacy 25% and 75%. 
Therapeutic use of neuraminidase 
inhibitors for all patients with 
influenzalike illness  
Gross attack rate of 30%; age-specific attack, 
hospitalization, and death rates as in regular 
epidemic; and 50% reduction of hospitalizations 
and deaths. 
Gross attack rate of 10% and 50%; age-specific 
attack rates (see Table 4); complication rates for a) 
persons <64 y of age times 2 and b) persons at low 
risk equal to persons at high risk.; and 25% to 75% 
reduction of hospitalizations and deaths. 
aMinimum variant based (9). 
bMaximum variant assumes 80% efficacy for all ages. Although neuraminidase inhibitors have proven to be
effective prophylactically (27,30–32), the specialists were
unanimous in their opinion that using neuraminidase
inhibitors prophylactically on a large scale in a pandemic
is not feasible because they need to be taken as long as the
threat of influenza virus infection lasts. The medication
would therefore need to be taken for at least several weeks
to several months in a pandemic. An enormous stockpile of
neuraminidase inhibitors would be required for the Dutch
population; compliance, in the course of time, would like-
ly diminish. In this scenario, using this medication for pro-
phylactic purposes might merely postpone the pandemic,
and the disease might emerge at the moment that most of
the population stops the prophylaxis unless an effective
and safe vaccine is available in sufficient amount at that
time.
The specialists considered neuraminidase inhibitors to
be more suitable than previous antiviral medicines (aman-
tadine and rimantadine), which lead to viral resistance,
have serious side effects, and are only effective against
influenza A (7,8,14). Neuraminidase inhibitors are effec-
tive against influenza A and B and have not generated
much resistance thus far (19,33,34); they appear to be safe
and have seldom caused serious side effects (34–36). 
Model and Data
Building a mathematical model of influenza spread is
difficult because of yearly differences in virus transmis-
sion and virulence, lack of understanding of the factors
affecting the spread of influenza, and shortage of popula-
tion-based data (9,37). We used a static model (12) that
estimates the numbers of hospitalizations and deaths in the
Netherlands by using data from earlier influenza epi-
demics and literature review. The model was implemented
by using an Excel spreadsheet (Microsoft Corp.,
Redmond, CA) (Figure 1). In the model, we distinguished
three age groups (<19 years, 20–64 years, and >65 years)
by low or high risk (susceptibility to the complications of
hospitalization and death) for influenza. The population
not protected against influenza depends on vaccination
coverage and vaccine and neuraminidase efficacy; all can
be different in each scenario. We calculated the number of
influenza cases in each age group at low or high risk for
influenza by multiplying numbers not protected against
influenza and attack rates. We calculated the absolute num-
ber of hospitalizations and deaths in each age group at low
or high risk for influenza by multiplying the calculated
number of influenza cases and the influenza-specific com-
plication (hospitalization or death) rates. The case-specific
complication rates in each age group at low or high risk for
influenza are computed from general population–specific
complication rates, current vaccination degree, and vac-
cine efficacy by assuming that during a regular epidemic
10% of the population becomes ill (12). The age distribu-
tion of the influenza cases in the general population is
assumed to be equal to the age distribution of persons con-
sulting their general practitioner for influenzalike illness.
Table 2 shows the values of the basic input variables.
Sensitivity Analyses
Sensitivity analyses were performed on the gross attack
rate, age-specific attack, hospitalization and death rates,
and on efficacy of vaccines and neuraminidase inhibitors.
Table 1 describes assumptions used in sensitivity analysis. 
Results
Results are shown in terms of number of hospitaliza-
tions and deaths (prevented) in relation to doses of vac-
cines or antiviral drugs needed. During a regular influenza
epidemic in the Netherlands, approximately 1,900 hospi-
talizations and 800 deaths related to influenza occur. The
nonintervention scenario of an influenza pandemic with a
gross attack rate of 30% and no interventions available
could lead to as many as 10,000 influenza-related hospital-
izations and >4,000 deaths (Figures 2 and 3). 
The influenza vaccination scenario could prevent
>6,000 (>60%) of hospitalizations and >2,200 (>55%) of
deaths. Vaccination of the total population requires 15.6
million doses of vaccine; vaccination only of risk groups
for influenza (including persons >65 years of age and
healthcare workers) requires 3.6 million vaccines. The
pneumoccoccal vaccination scenario, which requires 2.8
million doses of vaccine, could prevent 2,600 (25%) of the
hospitalizations and 140 (3.5%) of the deaths. The thera-
peutic use of neuraminidase inhibitors scenario could pre-
vent 5,000 hospitalizations and 2,000 deaths (assuming
50% efficacy) and would require 4.7 million prescriptions
of neuraminidase inhibitors. 
Adecrease (increase) in the gross attack rate to 10% (to
50%) shows a similar decrease (increase) in the absolute
number of expected hospitalizations and deaths. Assuming
different gross attack rates does not change the percentage
of hospitalizations and deaths that might be avoided in the
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Figure 1. Schematic view of calculation model used for scenario
analysis.different scenarios (Table 3). By using a range of age-spe-
cific attack rates (Table 4) for the nonintervention sce-
nario, we estimated that the number of hospitalizations
ranged from 7,500 to >19,000 and the number of deaths
from 2,700 to approximately 9,000 (Table 5). The variation
in the number of hospitalizations and deaths in each of the
scenarios is substantial. However, assuming different age-
specific attack rates leads to little difference in the percent-
age of hospitalizations and deaths that might be avoided by
a certain intervention. 
If one assumes that complication (i.e., hospitalization
and death) rates for low-risk persons are equal to the com-
plication rates for high-risk persons, the number of hospi-
talizations and deaths increases dramatically. In the nonin-
tervention scenario, we estimated >64,000 hospitalizations
(>10,000 in the base case) and approximately 10,000
deaths (approximately 4,000 in the base case). The number
of avoided hospitalizations ranges from almost 6,000 in
the pneumococcal vaccination scenario to >45,000 in the
influenza vaccination (of the total population) scenario,
and the number of avoided deaths ranges from 1,000 to
>6,000 (Table 6). In the scenario with influenza vaccina-
tion of risk groups, this assumption leads to a decrease in
the percentage of hospitalizations and deaths that might be
avoided, 21% (base case 61%) and 47% (base case 56%),
respectively. In the scenario with pneumococcal vaccina-
tion of risk groups, the percentage of hospitalizations and
deaths that might be avoided decreases to 9% (base case
31%) and 1% (base case 3%), respectively.
Low and high levels for age-specific influenza vaccine
efficacy show that the number of expected hospitalizations
varies from almost 2,000 to >6,900 and the number of
deaths varies from almost 800 to >2,800 (Table 7). These
numbers are equal to a range of 30% to 80% in the percent-
age of the number of hospitalizations and deaths that might
be avoided (base case 55% to 60%).
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Table 2. Input variables used to calculate potential impact of influenza pandemic in terms of healthcare outcomes and the effect of 
various interventions, the Netherlands 
Age groups (y) 
Input variable  <19  20–64  >65  Sources 
Population   3.8×10
6  9.7×10
6  2.1×10
6  Statistics Netherlands 
Population at high risk  0.09×10
6  0.6×10
6  0.7×10
6  (38–40) 
Age distribution of influenza cases   34.3  60.4  5.2  As in a regular epidemic in general practice (41)
a 
Current vaccination degree         (42,43) 
      Population at low risk  0.02  0.05  0.20   
      Population at high risk  0.65  0.75  0.80   
Efficacy influenza vaccine  80%  80%  80%  (13–15) 
Invasive pneumococcal infections        (12,16,17) 
     Related hospitalizations  50%  50%  50%   
     Efficacy vaccine  64%  64%  64%   
Hospitalization rate (per 100,000) for  influenza        As in a regular epidemic (44)
a 
     Population at low risk  0.1  0.1  2   
     Population at high risk  28  28  10   
Hospitalization rate (per 100,000) for influenza-
related pneumonia 
      As in a regular epidemic (44)
a 
     Population at low risk  0.3  0.3  38   
     Population at high risk  72  72  175   
Death rate (per 100,000)        As in a regular epidemic (45)
a 
     Low risk population  0.6  0.6  26.2   
     High risk population  29.6  29.6  84.9   
aAssuming that during a regular epidemic 10% of the population becomes ill. 
Figure 2. Number of hospitalizations and required prescriptions in
the various scenarios.For the pneumococcal vaccine scenario, we tested two
parameters: the percentage of complications (25% to 75%)
to be prevented by pneumococcal vaccination and the
pneumococcal vaccine efficacy (also 25% to 75%). Our
results showed that the number of expected hospitaliza-
tions varies from 5,400 to 8,950, the number of deaths
varies from >3,800 to 4,000 (Table 8). These values are
equal to a range of 12% to 47% (base case 31%) and 1%
to 5% (base case 3%) in the percentage of the number of
hospitalizations and deaths that might be avoided. When
assuming 25% to 75% effectiveness for the neuraminidase
inhibitors scenario, we also estimated that between 25%
and 75% of the number of hospitalizations and deaths can
be avoided.
Discussion
The nonintervention scenario describes a pandemic sit-
uation in which no interventions are available; such an
influenza pandemic, with a gross attack rate of 30%, would
result in five times as many influenza-related hospitaliza-
tions and deaths as in a regular influenza epidemic with the
current degree of vaccination, mostly in persons >65 years
of age. Sensitivity analysis shows that varying the gross
attack rate does not change the percentage of hospitaliza-
tions and deaths that might be avoided in the different sce-
narios. Varying the age-specific attack, hospitalization, and
death rates has a large impact on the estimated number of
hospitalizations and deaths. However, the impact is less in
terms of the percentage of the number of hospitalizations
and deaths that might be avoided by the various interven-
tions. 
Influenza vaccination may prevent many hospitaliza-
tions and deaths. The influenza vaccination scenario sug-
gests that when assuming the age-specific complication
rates of a regular epidemic, vaccination of the total popu-
lation compared to vaccination of healthcare workers and
the groups at risk for influenza would do little to avert hos-
pitalizations and deaths. However, sensitivity analysis
shows this result to be quite sensitive to the assumptions of
the complication rates by age. As a consequence of higher
complication rates in lower age and risk groups, the per-
centage of averted hospitalizations and deaths substantial-
ly decreases in the scenario’s pneumococcal and influenza
vaccination of risk groups for influenza. 
Only a pandemic itself can provide better estimates of
the age-specific attack and complication rates, but these
analyses show a range of what might be expected. While
the likelihood of an available influenza vaccine in the
Emerging Infectious Diseases • Vol. 9, No. 5, May 2003 535
RESEARCH
Figure 3. Number of deaths and required prescriptions in the vari-
ous scenarios.
Table 3. Hospitalizations and deaths in the scenario analysis of influenza pandemic
a 
No. of hospitalizations  No. of deaths 
Scenario  Base case 
Gross attack 
 rate 10% 
Gross attack  
rate 50%  Base case 




Nonintervention  10,186  3,395  16,977  4,040  1,347  6,733 
Influenza vaccination             
     Total population  3,847  1,282  6,412  1,738  579  2,896 
     Risk groups  3,968  1,223  6,614  1,789  596  2,981 
Pneumococcal vaccination  7,008  2,326  11,679  3,903  1,301  6,505 
Neuraminidase inhibitors  5,093  1,698  8,489  2,020  673  3,367 
aAssuming gross attack rates of 10% and 50%. 
Table 4. Alternative age-specific attack rates in scenario analysis for pandemic influenza, the Netherlands
a 
Age groups affected in proportion of 
Age (y) 
Age groups affected as in 
regular epidemic  Age groups equally affected  1:1:2  1:2:1  2:1:1  Previous pandemics
b 
<19    37.4  30.0  26.4  18.5  48.3  49.3 
20–64  28.6  30.0  26.4  37.0  24.1  25.6 
>65  23.1  30.0  52.9  18.5  24.1  15.0 
aGross attack rate 30%.
 
bDistribution from Meltzer et al. (9) based on previous pandemics. beginning of a pandemic is low, the next best option seems
to be the therapeutic use of neuraminidase inhibitors.
However, this option has three major considerations: 1)
effective use of neuraminidase inhibitors depends greatly
on the assumption of 50% effectiveness to prevent hospi-
talizations and deaths; 2) every patient with influenzalike
illness must begin medication within 48 hours after onset
of symptoms (a logistically complicated task); and 3) a
sufficient stock of neuraminidase inhibitors must be avail-
able, which is currently not the case. In our current
approach, we probably underestimated the effect of
influenza vaccination and the therapeutic use of neu-
raminidase inhibitors because we did not take into account
the specific features of influenza as an infectious transmis-
sible disease. 
Pneumococcal vaccination could prevent 31% of the
hospitalizations and 3.4% of the deaths. This intervention
is the least effective because pneumococcal vaccination
prevents only one complication of influenza (i.e., invasive
pneumococcal infections). In contrast to hospitalizations,
few deaths might be prevented by pneumococcal vaccina-
tion because relatively more excess hospitalizations than
deaths are attributable to influenza-related pneumonia. An
advantage of this intervention is that pneumococcal vacci-
nation can be done before the pandemic starts since the
vaccine is effective in preventing invasive pneumococcal
infections for approximately 5 years (15). As expected,
sensitivity analysis showed that lower vaccine effective-
ness results in less hospitalizations and deaths prevented.
In the next pandemic, if pneumoccocal infections occur
more often as a complication of influenza than in the base
case, using this intervention would prevent increased hos-
pitalizations and deaths.
The objective of our study was to examine the potential
impact (in terms of hospitalizations and deaths) of pan-
demic influenza in the Netherlands and to analyze the
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Table 5. Hospitalizations and deaths in various scenarios for alternative age-specific attack rates   
No. of hospitalizations per age group  No. of deaths per age group 


















Nonintervention  10,186  12,478  19,630  9,184  10,252  7,541  4.040  5,199  9,009  3,288  4,197  2,746 
Influenza vaccination                         
      Total population  3,847  4,844  8,068  3,285  3,939  2,716  1,738  2,245  3,929  1,401  1,809  1,169 
       Risk groups  3,968  4,962  8,171  3,410  4,058  2,840  1,789  2,294  3,972  1,454  1,860  1,222 
Pneumococcal 
vaccination 
7,008  8,574  13,460  6,323  7,053  5,200  3,903  5,015  8,697  3,178  4,054  2,654 
Neuraminidase 
inhibitors 
5,093  6,239  9,815  4,592  5,126  3,771  2,020  2,600  4,505  1,644  2,099  1,373 
aGross attack rate 30%.
 
bDistribution from Meltzer et al. (9) based on previous pandemics. 
Table 6. Hospitalizations and deaths in various scenarios for alternative complication rates
a 
No. of hospitalizations  No. of deaths 
Hospitalization and death rate  Hospitalization and death rate 
Scenario  Base case 
Age group 
<64 y x 2 
Low risk to high 
risk rate  Base case 
Age group 
<64 y x 2 
Low risk to high 
risk rate 
Nonintervention  10,186  12,830  64,425  4,040  4,207  10,087 
Influenza vaccination             
     Total population  3,847  4,376  16,798  1,738  1,771  3,981 
     Risk groups  3,968  4,617  50,935  1,789  1,873  5,333 
Pneumococcal vaccination  7,008  8,857  58,597  3,903  4,066  9,950 
Neuraminidase inhibitors  5,093  6,415  32,212  2,020  2,104  5,043 
aSee Table 1. 
Table 7. Hospitalizations and deaths for alternative influenza vaccine efficacy  
No. of hospitalizations  No. of deaths 
Vaccine efficacy  Vaccine efficacy 
Scenario  Base case 
All age groups 
equal to 80%
b 
Age groups <64 y =  
40%; for >65 = 30%
c  Base case 
All age groups 
equal to 80% 
Age groups <64 y = 
 40%; for >65 y = 30%
c 
Nonintervention  10,186  10,186  10,186  4,040  4,040  4,040 
Influenza vaccination             
     Total population  3,847  2,037  6,866  1,738  808  2,811 
     Risk groups  3,968  2,158  6,926  1,789  859  2,837 
aSee Table 1. 
bMinimum variant based on Meltzer et al. (9). 
cMaximum variant assumes 80% efficacy for all ages. effects of several possible interventions. Ideally, after a
pandemic has started, the influenza vaccine should be
available and administered as quickly as possible follow-
ing a prioritized scheme. In the Netherlands, developing
this scheme is a governmental task. The scheme may be
dependent on the actual (observed) age-specific attack and
complication rates. However, at the start of the pandemic,
no vaccine is expected to be available. Based on our analy-
sis and assumptions, we conclude that a combined strategy
of pneumococcal vaccination of risk groups for influenza
together with the therapeutic use of neuraminidase
inhibitors for all patients with influenzalike illness (within
48 hours after onset of symptoms) is the best strategy in
preventing hospitalizations and deaths.
This recommendation is not valid if therapeutic use of
neuraminidase inhibitors is shown to be ineffective in pre-
venting influenza-related hospitalizations and deaths.
Also, if the next pandemic shows that invasive pneumo-
coccal infections are not a complication of influenza,
pneumococcal vaccination is no longer a valid interven-
tion. Because these questions are still unanswered, we also
recommend ongoing research in the field of vaccine pro-
duction techniques. 
To prepare effectively for the next pandemic, the Dutch
government will continue to investigate stockpiling neu-
raminidase inhibitors and securing influenza vaccine sup-
ply during a pandemic. 
Our scenario analysis provides information about
reducing the effects of a pandemic to a minimum, both
regionally and nationally, to those who must prepare for
the control of an actual pandemic. The insights from the
scenario analysis provide a possible order of magnitude for
providing healthcare (regional data were also calculated;
data not shown). Furthermore, by using a model and a set
of assumptions, we compared the effects of various inter-
ventions on the demand for care. Scenario analysis provid-
ed insight into which parameters have the most influence
on the outcome variables (the age-specific attack and com-
plication rates). If outbreaks of a new, potentially pandem-
ic, influenza virus occur abroad and if these outbreaks
yield real information about the attack and complication
rates by age group, we can use these values in our model
to update the estimate of the demand for care that can be
expected in the Netherlands, nationally and regionally.
Other countries might also use a similar approach to sup-
port their pandemic preparedness planning.
Dr. van Genugten is a health economist at the National
Institute of Public Health and Environment (RIVM), Bilthoven,
the Netherlands. Her research interests include epidemic and pan-
demic intervention strategies.
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